Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Diocare Nasal Biome Defense Spray** is an intranasal natural product developed by Diomics together with Bonne Santé Group as part of the Diocare line of respiratory-support products launched during the COVID-19 period. The spray contains **Maritech Undaria pinnatifida**, a brown seaweed extract, and is positioned as a nutraceutical or natural nasal defense product rather than a conventional pharmaceutical. Its proposed mechanism is primarily **barrier-forming and mucosa-supportive**: application to the nasal cavity is intended to improve nasal moisture and create a protective layer that supports the body's natural defenses against respiratory viruses such as those associated with colds and influenza. It appears to be marketed for preventive or supportive upper respiratory use rather than as a targeted receptor-based therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diocare Nasal Biome Defense Spray.